Review and meta-analysis of randomized controlled clinical trials of remote ischemic preconditioning in cardiovascular surgery

Am J Cardiol. 2008 Dec 1;102(11):1487-8. doi: 10.1016/j.amjcard.2008.07.036. Epub 2008 Sep 4.

Abstract

To determine whether remote ischemic preconditioning (RIPC) is beneficial for patients who undergo cardiovascular surgery (CVS), a systematic review and meta-analysis of randomized controlled clinical trials of RIPC for the prevention of myocardial injury in CVS was performed. All prospective randomized controlled clinical trials of RIPC versus control that enrolled patients who underwent CVS were identified using a 2-level search strategy. First, a public-domain database (Medline) was searched using a Web-based search engine (PubMed). Second, relevant studies were identified through a manual search of secondary sources, including references of initially identified reports and a search of reviews and commentaries. The search identified 4 prospective randomized controlled clinical trials of RIPC versus control that enrolled patients who underwent CVS. In total, this meta-analysis included data on 184 patients who underwent CVS randomized to RIPC or control. Pooled analysis of the 4 trials demonstrated a statistically significant reduction in biomarkers of myocardial injury with RIPC relative to control (standardized mean difference -0.81, 95% confidence interval -1.29 to -0.33, p = 0.0010). In conclusion, the present study, the first systematic review and meta-analysis of randomized controlled clinical trials, demonstrated a statistically significant benefit of RIPC over control for reduction in biomarkers of myocardial injury in CVS patients.

Publication types

  • Meta-Analysis
  • Review
  • Systematic Review

MeSH terms

  • Biomarkers
  • Cardiovascular Surgical Procedures*
  • Humans
  • Ischemic Preconditioning, Myocardial*
  • Myocardial Ischemia / prevention & control*
  • Myocardial Reperfusion Injury / prevention & control*
  • Myocardium / pathology
  • Randomized Controlled Trials as Topic*

Substances

  • Biomarkers